Affiliations: Pathology & Tumour Biology, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK | Department of Histopathology and Molecular Pathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK | Institute of Pathology, University of Düsseldorf, Düsseldorf, Germany | Gemeinschaftspraxis Pathologie, Starnberg, Germany
Note: [] Corresponding author: Dr. Heike Grabsch, Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, Wellcome Trust Brenner Building, St. James's University Hospital, Beckett Street, Leeds LS9 7TF, UK. Tel.: +44 113 3438626; Fax: +44 113 3438431; E-mail: [email protected].
Abstract: Background: Patients with gastric cancer (GC) have a poor survival and biologicals such as Trastuzumab have not been used routinely in these patients. Existing data on HER2 expression and its clinical relevance in GC are still limited and controversial. Methods: HER2 expression was investigated by immunohistochemistry in 418 GC from Germany and 506 GC from England. Results were compared to clinicopathological parameters and patient survival. Results: Less than 10% of all GC showed HER2 expression in more than 5% of tumour cells and 91% of these were intestinal type GC. In both series, no relationship was found between HER2 expression, patient survival or TNM stage. Marked intratumoural heterogeneity was noted. Conclusions: This is the largest study to date demonstrating in two independent series that HER2 expression is not related to gastric cancer patient prognosis and that only a very small subgroup of intestinal type GC may potentially respond to HER2 targeting therapy. Due to prominent intratumoural heterogeneity of HER2 expression in GC, HER2 testing in endoscopic biopsies before treatment will be prone to false negative results.
